{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:25:34Z","timestamp":1765232734748,"version":"build-2065373602"},"reference-count":77,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.hoc.2019.04.002","type":"journal-article","created":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T16:19:33Z","timestamp":1558196373000},"page":"657-668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Peripheral T-Cell Lymphoma"],"prefix":"10.1016","volume":"33","author":[{"given":"Samuel Y.","family":"Ng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric D.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.hoc.2019.04.002_bib1","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","article-title":"How I treat the peripheral T-cell lymphomas","volume":"123","author":"Moskowitz","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2019.04.002_bib2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.hoc.2016.11.009","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a review of current disease understanding and therapeutic approaches","volume":"31","author":"Al-Zahrani","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"10.1016\/j.hoc.2019.04.002_bib3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.hoc.2016.11.001","article-title":"Management of anaplastic large cell lymphoma","volume":"31","author":"Chihara","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"10.1016\/j.hoc.2019.04.002_bib4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.hoc.2016.12.001","article-title":"Angioimmunoblastic T-cell lymphoma","volume":"31","author":"Broccoli","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"10.1016\/j.hoc.2019.04.002_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.hoc.2016.11.010","article-title":"T-cell prolymphocytic leukemia","volume":"31","author":"Sud","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"10.1016\/j.hoc.2019.04.002_bib6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.hoc.2016.11.004","article-title":"Uncommon variants of T-cell lymphomas","volume":"31","author":"Mehta-Shah","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"issue":"25","key":"10.1016\/j.hoc.2019.04.002_bib7","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.hoc.2019.04.002_bib8","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2019.04.002_bib9","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.hoc.2019.04.002_bib10","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"S1","key":"10.1016\/j.hoc.2019.04.002_bib11","first-page":"8507","article-title":"Allogenec or autologous transplantation as first-line therapy for younger patients with peripheral T-cell lymphoma\u2014results of the interim analysis of the AATT trial","volume":"33","author":"Schmitz","year":"2015","journal-title":"Hematol Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2019.04.002_bib12","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1021\/jm00067a020","article-title":"Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin","volume":"36","author":"DeGraw","year":"1993","journal-title":"J\u00a0Med Chem"},{"issue":"6","key":"10.1016\/j.hoc.2019.04.002_bib13","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/1042819031000077124","article-title":"Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression","volume":"44","author":"Wang","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"26","key":"10.1016\/j.hoc.2019.04.002_bib14","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","article-title":"Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies","volume":"27","author":"O'Connor","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2019.04.002_bib15","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2019.04.002_bib16","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.molonc.2012.09.003","article-title":"HDAC inhibitor-based therapies: can we interpret the code?","volume":"6","author":"New","year":"2012","journal-title":"Mol Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2019.04.002_bib17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","article-title":"Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies","volume":"24","author":"O'Connor","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2019.04.002_bib18","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood.V98.9.2865","article-title":"Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report","volume":"98","author":"Piekarz","year":"2001","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2019.04.002_bib19","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2019.04.002_bib20","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2019.04.002_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J\u00a0Hematol Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2019.04.002_bib22","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.hoc.2019.04.002_bib23","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.hoc.2019.04.002_bib24","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.hoc.2019.04.002_bib25","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"10168","key":"10.1016\/j.hoc.2019.04.002_bib26","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.hoc.2019.04.002_bib27","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/bjh.13855","article-title":"A\u00a0phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T-cell consortium trial","volume":"172","author":"Advani","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2019.04.002_bib28","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/S2352-3026(15)00023-X","article-title":"Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b\/2 study","volume":"2","author":"Dupuis","year":"2015","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.hoc.2019.04.002_bib29","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-14-2249","article-title":"Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma","volume":"21","author":"Jain","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2019.04.002_bib30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","article-title":"Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study","volume":"60","author":"Kim","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.hoc.2019.04.002_bib31","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2019.04.002_bib32","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2019.04.002_bib33","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma","volume":"121","author":"Toumishey","year":"2015","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.hoc.2019.04.002_bib34","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1182\/blood-2017-11-764357","article-title":"Novel insights into the pathogenesis of T-cell lymphomas","volume":"131","author":"Van Arnam","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2019.04.002_bib35","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev-pathol-020117-043821","article-title":"Pathogenesis of peripheral T\u00a0cell lymphoma","volume":"13","author":"Pizzi","year":"2018","journal-title":"Annu Rev Pathol"},{"issue":"4","key":"10.1016\/j.hoc.2019.04.002_bib36","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/nri3403","article-title":"T\u00a0cell receptor signalling networks: branched, diversified and bounded","volume":"13","author":"Brownlie","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.hoc.2019.04.002_bib37","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1084\/jem.20092042","article-title":"The fusion kinase ITK-SYK mimics a T\u00a0cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T\u00a0cell lymphoma","volume":"207","author":"Pechloff","year":"2010","journal-title":"J\u00a0Exp Med"},{"issue":"15","key":"10.1016\/j.hoc.2019.04.002_bib38","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1158\/0008-5472.CAN-08-3719","article-title":"The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease","volume":"70","author":"Dierks","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2019.04.002_bib39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3389\/fimmu.2013.00139","article-title":"Regulation of PI-3-kinase and Akt signaling in T lymphocytes and other cells by TNFR family molecules","volume":"4","author":"So","year":"2013","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.hoc.2019.04.002_bib40","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T\u00a0cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.hoc.2019.04.002_bib41","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ng.2872","article-title":"Somatic RHOA mutation in angioimmunoblastic T\u00a0cell lymphoma","volume":"46","author":"Sakata-Yanagimoto","year":"2014","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.hoc.2019.04.002_bib42","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ng.2916","article-title":"A\u00a0recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T\u00a0cell lymphoma","volume":"46","author":"Yoo","year":"2014","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.hoc.2019.04.002_bib43","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1172\/JCI92026","article-title":"Mutations in 5-methylcytosine oxidase TET2 and RhoA cooperatively disrupt T\u00a0cell homeostasis","volume":"127","author":"Zang","year":"2017","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.hoc.2019.04.002_bib44","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ccell.2018.01.001","article-title":"RHOA G17V induces T\u00a0follicular helper cell specification and promotes lymphomagenesis","volume":"33","author":"Cortes","year":"2018","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.hoc.2019.04.002_bib45","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood-2017-11-818617","article-title":"RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice","volume":"132","author":"Ng","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2019.04.002_bib46","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-immunol-110416-120628","article-title":"Disorders of the JAK\/STAT pathway in T\u00a0cell lymphoma pathogenesis: implications for immunotherapy","volume":"35","author":"Waldmann","year":"2017","journal-title":"Annu Rev Immunol"},{"issue":"20","key":"10.1016\/j.hoc.2019.04.002_bib47","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood-2014-04-566687","article-title":"JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model","volume":"124","author":"Degryse","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2019.04.002_bib48","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1084\/jem.20021548","article-title":"Stat5 synergizes with T\u00a0cell receptor\/antigen stimulation in the development of lymphoblastic lymphoma","volume":"198","author":"Kelly","year":"2003","journal-title":"J\u00a0Exp Med"},{"issue":"6","key":"10.1016\/j.hoc.2019.04.002_bib49","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/mt.2013.67","article-title":"Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1","volume":"21","author":"Heinrich","year":"2013","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.hoc.2019.04.002_bib50","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nm1249","article-title":"Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target","volume":"11","author":"Chiarle","year":"2005","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.hoc.2019.04.002_bib51","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrg.2017.33","article-title":"TET-mediated active DNA demethylation: mechanism, function and beyond","volume":"18","author":"Wu","year":"2017","journal-title":"Nat Rev Genet"},{"issue":"3","key":"10.1016\/j.hoc.2019.04.002_bib52","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nrc3895","article-title":"DNMT3A in haematological malignancies","volume":"15","author":"Yang","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2019.04.002_bib53","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/MOH.0000000000000261","article-title":"The curious origins of angioimmunoblastic T-cell lymphoma","volume":"23","author":"Cortes","year":"2016","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.hoc.2019.04.002_bib54","doi-asserted-by":"crossref","first-page":"15102","DOI":"10.1038\/ncomms15102","article-title":"Tet2 loss leads to hypermutagenicity in haematopoietic stem\/progenitor cells","volume":"8","author":"Pan","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.hoc.2019.04.002_bib55","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1038\/bcj.2014.83","article-title":"Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice","volume":"4","author":"Muto","year":"2014","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.hoc.2019.04.002_bib56","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/leu.2016.29","article-title":"DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice","volume":"30","author":"Scourzic","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2019.04.002_bib57","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/10428190601137658","article-title":"Angioimmunoblastic T\u00a0cell lymphoma: treatment experience with cyclosporine","volume":"48","author":"Advani","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.hoc.2019.04.002_bib58","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1084\/jem.20070366","article-title":"Phosphoinositide 3-kinase gamma participates in T\u00a0cell receptor-induced T\u00a0cell activation","volume":"204","author":"Alcazar","year":"2007","journal-title":"J\u00a0Exp Med"},{"issue":"8","key":"10.1016\/j.hoc.2019.04.002_bib59","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-delta,gamma inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2019.04.002_bib60","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/blood-2018-99-115241","article-title":"The combination of duvelisib, a PI3K-\u03b4,\u03b3 inhibitor, and romidepsin is highly active in relapsed\/refractory peripheral T-cell lymphoma with low rates of transaminitis: results of parallel multicenter, phase 1 combination studies with expansion cohorts","volume":"132","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2019.04.002_bib61","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1084\/jem.20110283","article-title":"Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas","volume":"208","author":"Pilati","year":"2011","journal-title":"J\u00a0Exp Med"},{"issue":"20","key":"10.1016\/j.hoc.2019.04.002_bib62","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa1114885","article-title":"Somatic STAT3 mutations in large granular lymphocytic leukemia","volume":"366","author":"Koskela","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2019.04.002_bib63","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1038\/leu.2015.280","article-title":"Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia","volume":"29","author":"Bilori","year":"2015","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2019.04.002_bib64","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/blood-2018-99-119944","article-title":"The novel SYK\/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in a phase 2a study in relapsed\/refractory peripheral T-Cell lymphoma and cutaneous T-cell lymphoma","volume":"132","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.hoc.2019.04.002_bib65","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","article-title":"TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2019.04.002_bib66","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2019.04.002_bib67","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1182\/blood-2018-99-116605","article-title":"Combined hypomethylating agents (HMA) and histone deacetylase inhibitors (HDACi) exhibit compelling activity in patients with peripheral T-cell lymphoma (PTCL) with high complete response rates in angioimmunoblastic T-cell lymphoma (AITL)","volume":"132","author":"Falchi","year":"2018","journal-title":"Blood"},{"issue":"6382","key":"10.1016\/j.hoc.2019.04.002_bib68","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T\u00a0cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"6382","key":"10.1016\/j.hoc.2019.04.002_bib69","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.hoc.2019.04.002_bib70","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1016\/j.hoc.2019.04.002_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10090339","article-title":"Current immunotherapeutic approaches in T\u00a0cell non-Hodgkin lymphomas","volume":"10","author":"Poggio","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.hoc.2019.04.002_bib72","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T\u00a0cell receptor beta-chain constant region for immunotherapy of T\u00a0cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.hoc.2019.04.002_bib73","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T\u00a0cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2019.04.002_bib74","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2019.04.002_bib75","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T\u00a0cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"issue":"7683","key":"10.1016\/j.hoc.2019.04.002_bib76","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nature24649","article-title":"PD-1 is a haploinsufficient suppressor of T\u00a0cell lymphomagenesis","volume":"552","author":"Wartewig","year":"2017","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.hoc.2019.04.002_bib77","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy","volume":"171","author":"Palmer","year":"2017","journal-title":"Cell"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985881930053X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985881930053X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:12:06Z","timestamp":1760184726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985881930053X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S088985881930053X"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2019.04.002","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral T-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2019.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}